superficie ocular 6 - Laboratorios Thea

32
Diseases:Inmunology of Bullous Oculo-Muco-Cutaneous Disorder. Buren, The Netherlands: Aeolus
Press.1997:95-152.
22. Azzarolo AM, Micheff AK, Kaswan RL, et all. Androgen support of lacrimal gland function. Endocrine
1997;6:39-45.
23. Ke-Ping Xu MD, Yukiko Yagi ORT, Ikuko Toda MD.Tear function Index. Arch Ophthalmol 1995. 113: 84-
88.
24. Stephen BK, Gillian S, Colin W, Field A. Modification of the tear function index and its use in the diagnosis
of the Sjögren´s syndrome. Br J Opthalmol 2001;85:193-199.
25. Calonge M. The treatment of dry eye. Surv Ophthalmol 2001; 45 suppl:227-239.
26. Basu PK.Affected by cigarette smoke. Ophthalmol Times. 1977.
27. Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency.
Ophthalmology 106:939-43.1999.
28. Lopez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and
preservatives. Curr Eye Res 10:645-56.1991.
29. Tripathi BJ, Tripathi RC. Cytotoxic effect of benzalkonium chloride and chlorobutanol on human corneal epithelial
cells in vitro. Lens Eye Toxic Res 1989; 6;395-403.
30. Donate J, Benítez del Castillo JM, Fernández C, García Sánchez J. Validación cuestionario para diagnóstico
ojo seco. Arch Soc Esp Oftalmol 2002; 77:493-500.
31. Carney LG, Hill RM. Human tear buffering capacity. Arch Opthalmol 97:951-2. 1979.
32. Harada M. Secretion of human tear lysozyme Acta Soc Ophthalmol Jap1978. 82:308-314.
33. Gobbels M, Selbach J, Spitznas M. Effect of eledoisin on tear volumen and tear flow in humans as assessed by
fluorophotometry. Graefes Arch Clin Exp Ophthalmol. 1991.229:549-52.
34. Mathers WD, Dolney AM. Objetive demonstration of tear stimulation with oral pilocarpine in dry eye patients.
Invest Opthalmol Vis Sci.2000;41:S 60.
35. Yerxa BR, Zhang VZ, Sheridan L. Cellular localization of P2Y2 receptor gene expresion in primate tissues by
nonisotopic in situ hybridization . Invest Ophthalmol Vis Sci 2000;41:S 871.
36. Tsubota K, Saito I, Ishimaru N, Hayashi Y. Use of topical cyclosporin A in a primary Sjögren syndrome mouse
model. Invest Ophthalmol Vis Sci 1998;39:155-9.
37. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren syndrome.
Acta Ophthalmol.1994; 72:438-42.
38. Sullivan DA, Edwards JA. Androgen stimulation of lacrimal gland function in mouse models of Sjögren syndrome.
J Steroid Biochem Mol Biol 1997; 60:237-45.
39. Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM: Successful use of topical retinoic acid in severe dry eye
due to chronic graft-versus-host disease. Bone Marrow Transplant 1996; 18:641-2.
40. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjögren syndrome: a
preliminary report. J Rheumatol 1997;24: 1842-3.
41. Sahlin S, Chen E, Kaugesaar T, et all. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J
Ophthalmaol 2000;129:481-6.
42. Lemp MA. Basic principles and classification of dry eye. En: Lemp MA, Marquart, eds. The dry eye. A comprehensive
guide.1992.Heidelberg:Springer Verlag 101-130.
43. Lemp M. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye. CLAO J 1995.
44. Liotet S, Kogbe O, laroche L, Lafont M, Thenot JC. Utilidad de la impresión conjuntival. Arch Soc Esp
Oftalmol 1988; 54:301-306.
45. Rivas L, Oroza MA, Álvarez MI, Pérez Esteban A, Rodríguez JJ, Murube J. Alteraciones de la superficie ocular
en personas con queratoconjuntivitis sicca, por citología de impresión. Arch Soc Esp Oftalmol 1991; 60:
183-188.
46. Rolando M, Macri A, Alongi S, Trillo C, Calabria G. Use of a questionaire for the diagnosis of tear film related
ocular surface disease. In: Lacrimal gland, Tear film and dry eye Syndromes. D Sullivan ed. 1997. Plenum
Press, New York.
47. Sánchez- Jara Luengo J, Franco Sánchez A, Barahona Hortelano JM. Alteraciones corneales producidas por la
amiodarona. Arch Soc Esp Oftalmol 1982;43:458-464.
48. Simón Castellví JM, Vergés C, Cammins JL, Pita Salorio D. Tratamiento del síndrome de ojo seco. Análisis
comparativo. Arch Soc Esp Oftalmol 1989;56: 185-192.
49. Pedraza A et al; Ácidos grasos w3 y w6, tratamiento de la sequedad ocular; Comunicación nº 17 presentada
en el 78 Congreso de la Sociedad Española de Oftalmología 2002.
50. Horrobin DF et al; Sjogren’s syndrome and the sicca syndrome: the role of prostaglandin E1 deficiency.
Treatment with essential fatty acids and vitamin C; Medical Hypotheses 1980; 6:225-232.
51. Frank A Bucci Jr; Efecto sobre los niveles de lactoferrina lagrimal de la ingesta continuada preoperatoria y postoperatoria
de ácidos grasos omega por vía oral en pacientes intervenidos de LASIK bilateral. Abstract 272;
Symposium on Cataract, IOL and Refractiv Surgery, April 12-16, 2003; San Francisco, California.